---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-113960"
form_type: "8-K"
ticker: "TCRT"
cik: "0001107421"
company_name: "Alaunos Therapeutics, Inc."
filed_at: "2024-10-10T23:59:59+00:00"
generated_at: "2026-05-30T16:16:47.618514+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Alaunos terminates key license with Precigen, pivots to oral obesity program; cash runway into Q1 2025

## Summary
- Terminated Amended and Restated License Agreement with Precigen effective Oct 4, 2024; Sleeping Beauty patent expiry in 2026 cited.
- Continues prosecuting TCR IP targeting KRAS, TP53, EGFR mutations and hunTR discovery platform.
- Exploring strategic alternatives including acquisition, merger, reverse merger, or sale of assets.
- Progressing internally developed small molecule oral obesity program; CMDO engaged for API manufacturing.
- Cash runway extended into Q1 2025 via overhead reductions; in vitro testing planned Q4 2024.

## SEC filing metadata
- accession: 0000950170-24-113960
- form_type: 8-K
- ticker: TCRT
- cik: 0001107421
- company_name: Alaunos Therapeutics, Inc.
- filed_at: 2024-10-10T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.02, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1107421/000095017024113960/0000950170-24-113960-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1107421/000095017024113960/tcrt-20241004.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-113960
- JSON: https://secwatch.observer/filing/0000950170-24-113960.json
- Plain text: https://secwatch.observer/filing/0000950170-24-113960.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.